The PML Consortium formed among several pharmaceutical companies to prevent and treat a rare disease that emerged among patients taking immunomodulatory drugs. It could offer a model for finding solutions for adverse drug reactions.
Pharmaceutical companies compete, but sometimes collaboration is important, too. A new commentary in Advances in Therapy highlights how a consortium formed (and then disbanded) to address a rare disease that appears as a severe reaction to immunomodulatory therapies.
Progressive multifocal leukoencephalopathy (PML) is a possibly fatal inflammation of the white matter in the brain caused by the JC virus, and occurs in patients who already have weakened immune systems. As PML emerged in the mid-2000s, multiple drug companies formed the PML Consortium to find ways to prevent or treat this disease.
The authors explain that while PML was long recognized as a risk for patients with HIV, it emerged among patients with multiple sclerosis as they began to take natalizumab, then among more patients taking other new immunomodulatory drugs. The PML Consortium’s first members were Roche, Elan, and Biogen Idec; later, Pfizer, Takeda, MedImmune, and Bristol-Myers signed on to share information and collaborate in other ways.
The authors state that the PML Consortium not only succeeded, but it is also a model for other joint efforts to address adverse reactions to new drug classes.
Among the consortium activities outlined in the commentary:
Since 2009, the authors wrote, “The ability to stratify PML risk improved, enhanced risk management plans were implemented, and increased awareness helped support earlier intervention.”
In this manner, the group reduced the need for urgency for a breakthrough to treat PML, but in doing so, this also limited the group’s ability to sustain research efforts. The board disbanded the consortium “after 8 years of intense collaboration.”
The authors state that board members and scientific advisory board members see the consortium as a model worth repeating, particularly when new drug classes produce adverse events. “It allows researchers from across sectors to work together in ways they could not otherwise,” they wrote. “Furthermore, this model has value because it enables more effective use of resources,” which brings progress more quickly than would occur otherwise.
Reference
Peterson IS, Iverson Wo, Kasaian MT, Liu M. The progressive multifocal leukoencephalopathy consortium as a model for advancing research and dialogue on rare severe adverse drug reactions [published online February 13, 2019]. Adv Ther. doi:org/10.1007/s12325-019-0886-2.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More